Use of α,25-Dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma

Human Immunology

Volumn 71, Issue 7, 2010, Pages 659-665

  Walsh, Jarrett E ^a,b   Clark, Anna Maria ^a,b   Day, Terry A ^b   Gillespie, M Boyd ^b   Young, M Rita I ^a,b,c  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b Department of Otolaryngology Head and Neck Surgery ^*  (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Head and neck cancer; Head and neck squamous cell carcinoma; Recurrence; T cell, vitamin D

Indexed keywords

CALCITRIOL; CD69 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFICACY; FEMALE; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; MALE; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PILOT STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LECTINS, C-TYPE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 77953916257     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.04.008     Document Type: Article

References (37)

1. Heimdal J.H., Aarstad H.J., Klementsen B., Olofsson J. Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumour stage and prognosis. Acta Otolaryngol 1999, 119:281-284.
2. + T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003, 63:1555-1559.
3. De Stefani A., Valente G., Forni G., Lerda W., Ragona R., Cortesina G. Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: Clinical and pathologic correlations. J Immunother Emphasis Tumor Immunol 1996, 19:125-133. [PubMed].
4. van Herpen C.M., Looman M., Zonneveld M., Scharenborg N., de Wilde P.C., van de L.L., et al. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 2004, 10:2626-2635.
5. Karcher J., Dyckhoff G., Beckhove P., Reisser C., Brysch M., Ziouta Y., et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 2004, 64:8057-8061.
6. To W.C., Wood B.G., Krauss J.C., Strome M., Esclamado R.M., Lavertu P., et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: A phase 1 study. Arch Otolaryngol Head Neck Surg 2000, 126:1225-1231.
7. Hadden J., Verastegui E., Barrera J.L., Kurman M., Meneses A., Zinser J.W., et al. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol 2003, 3:1073-1081.
8. Wanebo H.J., Riley T., Karz D., Pace R.C., Johns M.E., Cantrell R.W. Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell. Cancer 1988, 61:462-474.
9. Lathers D.M.R., Achille N.J., Young M.R.I. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 2003, 64:1160-1166.
10. Strauss L., Volland D., Kunkel M., Reichert T.E. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): Possible link between angiogenesis and immune tolerance. Med Sci Monit 2005, 11:BR280-BR292.
11. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6:1755-1766.
12. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103.
13. + cells. Int J Cancer 1997, 73:663-669.
14. + cells of tumor bearers from dendritic toward monocytic cells, and the induction of differentiation toward dendritic cells by 1a,25-dihydroxyvitamin D. 3. Int J Immunopharmacol 1999, 21:675-688.
15. Benvenuti F., Lagaudriere-Gesbert C., Grandjean I., Jancic C., Hivroz C., Trautmann A., et al. Dendritic cell maturation controls adhesion, synapse formation, and the duration of the interactions with naive T lymphocytes. J Immunol 2004, 172:292-301.
16. Asai T., Storkus W.J., Mueller-Berghaus J., Knapp W., DeLeo A.B., Chikamatsu K., Whiteside T.L. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immun 2002, 2:3.
17. Young M.R., Neville B.W., Chi A.C., Lathers D.M., Boyd G.M., Day T.A. Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma. Cancer Immunol Immunother 2007, 56:1077-1086.
18. Ohm J.E., Shurin M.R., Esche C., Lotze M.T., Carbone D.P., Gabrilovich D.I. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999, 163:3260-3268.
19. Kulbersh J.S., Day T.A., Gillespie M.B., Young M.R. 1a,25-Dihydroxyvitamin D3 to skew intratumora levels of immune inhibitory CD34+ progenitor cells into dendritic cells. Otolaryngol Head Neck Surg 2009, 140:235-240.
20. Muindi J.R., Peng Y., Potter D.M., Hershberger P.A., Tauch J.S., Capozzoli M.J., et al. Pharmacokinetics of high-dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002, 72:648-659.
21. Caras I., Grigorescu A., Stavaru C., Radu D.L., Mogos I., Szegli G., Salageanu A. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 2004, 53:1146-1152.
22. Kuss I., Hathaway B., Ferris R.L., Gooding W., Whiteside T.L. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol 2005, 62:161-172.
23. Molling J.W., Langius J.A., Langendijk J.A., Leemans C.R., Bontkes H.J., van der Vliet H.J., et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007, 25:862-868.
24. Aue G., Njuguna N., Tian X., Soto S., Hughes T., Vire B., et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009, 94:1266-1273.
25. Freeman C.M., Martinez F.J., Han M.K., Ames T.M., Chensue S.W., Todt J.C., et al. Lung dendritic cell expression of maturation molecules increases with worsening COPD. Am J Respir Crit Care Med 2009, 180:1179-1188.
26. Lopez-Albaitero A., Lee S.C., Morgan S., Grandis J.R., Gooding W.E., Ferrone S., Ferris R.L. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009, 58:1855-1864.
27. Bergmann C., Strauss L., Zeidler R., Lang S., Whiteside T.L. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007, 67:8865-8873.
28. Kacani L., Wurm M., Schennach H., Braun I., Andrle J., Sprinzl G.M. Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes. Oral Oncol 2003, 39:672-679.
29. + immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol 2000, 109:749-754.
30. Young M.R., Lathers D.M. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol 1999, 21:241-252.
31. Young M.R.I., Wright M.A., Lozano Y., Matthews J.P., Benefield J., Prechel M.M. Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer. Int J Cancer 1996, 67:333-338.
32. Rejnmark L., Tietze A., Vestergaard P., Buhl L., Lehbrink M., Heickendorff L., Mosekilde L. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: A nested case-control study. Cancer Epidemiol Biomarkers Prev 2009, 18:2655-2660.
33. Goldstein B.D., Kurt R.A. Dietary vitamin D3 restriction influences tumor growth, but not the ability to generate an antigen-specific immune response in OTII transgenic mice. Immunol Invest 2009, 38:365-382.
34. Lathers D.M., Clark J.I., Achille N.J., Young M.R. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother 2004, 53:422-430.
35. Enioutina E.Y., Bareyan D., Daynes R.A. Vitamin D3-mediated alterations to myeloid dendritic cell trafficking in vivo expand the scope of their antigen presenting properties. Vaccine 2007, 25:1236-1249.
36. Froicu M., Weaver V., Wynn T.A., McDowell M.A., Welsh J.E., Cantorna M.T. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003, 17:2386-2392.
37. Vulcano M., Struyf S., Scapini P., Cassatella M., Bernasconi S., Bonecchi R., et al. Unique regulation of CCL18 production by maturing dendritic cells. J Immunol 2003, 170:3843-3849.